Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2).
Silverberg JI, Mustapa MN, Reid F, Lei A, Smith R, Moate R, Kelly A, Chen R, Gavala M, Jimenez E, Belvisi MG, Sadiq MW, Kell C, Pandya HC.
Silverberg JI, et al. Among authors: pandya hc.
J Eur Acad Dermatol Venereol. 2024 Nov 13. doi: 10.1111/jdv.20388. Online ahead of print.
J Eur Acad Dermatol Venereol. 2024.
PMID: 39535462